About: Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development
Creator	Li, Jia Pang, Zhiqing Zhu, Yuefei
Source	Elsevier; Medline; PMC
abstract	SARS-CoV-2 has been marked as a highly pathogenic coronavirus of COVID-19 disease into the human population, causing over 5.5 million confirmed cases worldwide. As COVID-19 has posed a global threat with significant human casualties and severe economic losses, there is a pressing demand to further understand the current situation and develop rational strategies to contain the drastic spread of the virus. Although there are no specific antiviral therapies that have proven effective in randomized clinical trials, currently, the rapid detection technology along with several promising therapeutics for COVID-19 have mitigated its drastic transmission. Besides, global institutions and corporations have commenced to parse out effective vaccines for the prevention of COVID-19. Herein, the present review will give exhaustive details of extensive researches concerning the drug discovery and therapeutic options for COVID-19 as well as some insightful discussions of the status of COVID-19.
has issue date	2020-07-04(xsd:dateTime)
bibo:doi	10.1016/j.ajps.2020.06.001
bibo:pmid	32837565
has license	no-cc
sha1sum (hex)	5b804f88f68fa6a81bf634c6740ff79253ba471a
schema:url	https://doi.org/10.1016/j.ajps.2020.06.001
resource representing a document's title	Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development
has PubMed Central identifier	PMC7335243
has PubMed identifier	32837565
schema:publication	Asian J Pharm Sci
resource representing a document's body	covid:5b804f88f68fa6a81bf634c6740ff79253ba471a#body_text
is schema:about of	named entity 'vaccine' named entity 'Journal' named entity 'emerging' named entity 'insights' named entity 'COVID-19' named entity 'drug discovery' named entity 'drug discovery' named entity 'cysteine' named entity 'vaccine' named entity 'animal species' named entity 'yellow fever' named entity 'SARS-CoV-2' named entity 'chloroquine' named entity 'vaccine' named entity 'polyprotein' named entity 'Chloroquine' named entity 'SARS-CoV-2' named entity 'EC50' named entity 'mAbs' named entity 'CEPI' named entity 'gene' named entity 'pneumonia' named entity 'respiratory syncytial virus infections' named entity 'amino acid' named entity 'cytokines' named entity 'SARS-CoV-2' named entity 'RdRp' named entity 'antiviral drug' named entity 'SARS-CoV-2' named entity 'mortality rate' named entity 'SARS-CoV-2' named entity 'glycoprotein' named entity 'SARS-CoV-2' named entity 'infectivity' named entity 'SARS-CoV-2' named entity 'neoteric' named entity 'protease' named entity 'protein' named entity 'adverse effects' named entity 'murine' named entity 'pseudotyped' named entity 'ribavirin' named entity 'chloroquine' named entity 'IL-6 receptor' named entity 'acyl chain' named entity 'PCR testing' named entity 'pro-inflammatory cytokines' named entity 'cyclophilin' named entity 'PCR' named entity 'immunogenicity' named entity 'SARS-CoV-2' named entity '28 May' named entity 'CEPI' named entity 'Subunit vaccines' named entity 'SARS-CoV-2' named entity 'RdRp' named entity 'SARS-CoV' named entity 'ssRNA' named entity 'bat' named entity 'neutralizing antibodies' named entity 'WHO' named entity 'physiologically based pharmacokinetic' named entity 'Traditional Chinese Medicine' named entity 'viremia' named entity 'siRNAs' named entity 'ACE2' named entity 'structure-based design' named entity 'immunomodulation' named entity 'critical role' named entity 'GRP78' named entity 'host tropism' named entity 'COVID-19' named entity 'SARS' named entity 'viral infections' named entity 'sterol' named entity 'clinical trial' named entity 'epidemiology' named entity 'drug target' named entity 'corticosteroids'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software